These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19035301)

  • 1. Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1.
    Oei AL; Sweep FC; Geurts-Moespot A; van Tienoven D; Von Mensdorff-Pouilly S; Thomas CM; Massuger LF
    Anticancer Res; 2008; 28(5A):2721-5. PubMed ID: 19035301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of ELISAs for quantification of HMFG1-specific human anti-mouse IgG and IgM antibodies.
    Oei AL; Boerman OC; Geurts-Moespot A; van Eerd JE; van Tienoven D; Courtenay-Luck N; Thomas CM; Massuger LF; Sweep FC
    Int J Biol Markers; 2007; 22(3):167-71. PubMed ID: 17922458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.
    Kosmas C; Maraveyas A; Gooden CS; Snook D; Epenetos AA
    J Nucl Med; 1995 May; 36(5):746-53. PubMed ID: 7738643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer.
    Oei AL; Moreno M; Verheijen RH; Sweep FC; Thomas CM; Massuger LF; von Mensdorff-Pouilly S
    Int J Cancer; 2008 Oct; 123(8):1848-53. PubMed ID: 18661524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
    Ng B; Kramer E; Liebes L; Wasserheit C; Hochster H; Blank E; Ceriani R; Furmanski P
    Cancer Res; 2001 Apr; 61(7):2996-3001. PubMed ID: 11306478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
    Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
    Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
    Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
    Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
    Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?
    Grana C; Bartolomei M; Handkiewicz D; Rocca P; Bodei L; Colombo N; Chinol M; Mangioni C; Malavasi F; Paganelli G
    Gynecol Oncol; 2004 Jun; 93(3):691-8. PubMed ID: 15196866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
    Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
    Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
    Richman CM; DeNardo SJ; O'Donnell RT; Goldstein DS; Shen S; Kukis DL; Kroger LA; Yuan A; Boniface GR; Griffith IJ; DeNardo GL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    Cancer Biother Radiopharm; 2000 Feb; 15(1):53-64. PubMed ID: 10740653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4.
    Schmidberger H; Buchsbaum DJ; Blazar BR; Everson P; Vallera DA
    Cancer Res; 1991 Apr; 51(7):1883-90. PubMed ID: 2004371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.
    Masters GR; Berger MA; Albone EF
    Gynecol Oncol; 2006 Sep; 102(3):462-7. PubMed ID: 16434088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.